4-Bromo-3,5-dimethylphenol | CAS:7463-51-6

We serve 4-Bromo-3,5-dimethylphenol CAS:7463-51-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Bromo-3,5-dimethylphenol

Chemical Name:4-Bromo-3,5-dimethylphenol
CAS.NO:7463-51-6
Synonyms:4-Bromo-3,5-dimethylphenol
3,5-dimethyl-4-bromophenol
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 267.3±35.0 °C at 760 mmHg
Melting Point 113-115 °C(lit.)
Molecular Formula C8H9BrO
Molecular Weight 201.061
Flash Point 115.4±25.9 °C
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.580
 
Specification:
Appearance:White powder
Assay:≥98.5%
Melting Point:113-116°C
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:4-Bromo-3,5-dimethylphenol is used as a reactant in the synthesis of chromen-4-one and isoflavone scaffolds.



Contact us for information like 4-Bromo-3,5-dimethylphenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,5-dimethyl-4-bromophenol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,5-dimethyl-4-bromophenol Use and application,3,5-dimethyl-4-bromophenol technical grade,usp/ep/jp grade.


Related News: If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role.2,6-Bis[(2-Hydroxyethyl)Amino]Toluene manufacturer Chinese officials on Sunday reported a surge in new cases.1-formylpiperidine-4-carboxylic acid supplier If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such.3-Mercaptopropylmethyldimethoxysilane vendor Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.